

AlphaVBeta3 Integrin Expression within Uterine Endometrium in Unexplained Infertility

Thesis

Submitted for partial fulfillment of Master Degree
in Obstetrics and Gynecology

By

Alaa Mohamed Atef Karim El-Din

*Resident of Obstetrics and Gynecology
Ain Shams Maternity Hospital*

Supervised by

Prof. Mohamed Sayed Ali Salem

*Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University*

Dr. Mohamed Abdel Hameed Abdel Hafeez

*Lecturer of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2015



Acknowledgment

Thanks are all to Allah, The Compassionate and the Merciful, for helping me finish this work, and for blessing me throughout my life by His Compassion and Generosity.

*Words fail to express my great indebtedness to **Professor/ Mohamed Sayed Aly Salem**, Professor of Obstetrics and Gynecology, Ain Shams University, whose continuous supervision, advice and fruitful criticism have been of great help in performing this work, and from whom I always learn a lot of lessons in my whole life.*

*I would like to express my sincere appreciation to **Doctor/ Mohammed Abdel-Hafeez**, Lecturer of Obstetrics and Gynaecology, Ain Shams University, for his continuous guidance, patience, experienced advice and great encouragement which has been of the most valuable and to whom I will always be indebted.*

*A great appreciation and most gratefulness for **Professor/ Magda Mourad El Sayed Hassan**, Professor of Pathology, National Cancer Institute, Cairo University, for her supervision and participation in this work, without her honest assistance and abundant patience, this work would have never come to light.*

*Last but not least I would like to express my best regards and thanks to all who gave me a hand while working on this research and I'd like to dedicate this work to my beloved **Family** who supported me to complete this work.*

Alaa Mohamed Atef Karim El-Din



List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables	iv
List of Figures	v
Protocol.....	
Introduction	1
Aim of the Work	6
Review of Literature	
➤ Unexplained Infertility	7
➤ Endometrial Role in Receptivity	22
- Endometrial histology	22
- Biochemical and molecular markers of Endometrial Receptivity	29
-Ultrasonography and endometrial receptivity	78
➤ Integrins	84
Patients and Methods	124
Results.....	141
Discussion	153
Summary	164
Conclusion	168
Recommendations.....	169
References.....	170
Arabic Summary.....	—

List of Abbreviations

- **2D** : Two dimensional
- **3D** : Three dimensional
- **4D** : Four dimensional
- **BBT** : Basal body temperature
- **CAMP** : Cyclic Adenosine Monophosphate
- **CAMs** : Cell Adhesion Molecules
- **CC** : Clomiphene Citrate
- **COH** : Controlled ovarian stimulation
- **COX** : Cyclooxygenase
- **cPLA** : Cytosolic Phospholipase A
- **CSF** : Colony Stimulating Factor
- **ECM** : Extracellular matrix components
- **EDPA** : Intraendometrial power Doppler area.
- **EEC** : Endometrial Epithelial cells
- **ELISA** : Enzyme-linked immunosorbent assay
- **ER** : Estrogen receptor
- **ER** : Estrogen receptor
- **ESC** : Endometrial Stromal Cells
- **ET** : Embryo transfer
- **ET** : Endometrial thickness
- **EV** : Endometrial volume
- **FAK** : Focal adhesion kinase
- **FN** : Fibronectin

List of Abbreviations (Cont.)

- **FSH** : Follicle Stimulation Hormone
- **HG-EGF** : Heparin binding epidermal growth factor
- **HOXA** : Homeobox gene
- **HSG** : Human Chorionic Gonadotrophin
- **HSG** : Hysterosalpingography
- **ICAM-1** : Intercellular adhesion molecules 1
- **ICSI** : Intracytoplasmic Sperm Injection
- **IGF** : Insulin like growth factor
- **IHC** : Immunohistochemistry
- **IL** : Interlukin
- **ILK** : Integrin linked kinase
- **IUD** : Intrauterine Device
- **IUI** : Intrauterine Insemination
- **IVF** : In Vitro fertilization
- **LH** : Luteinizing Hormone
- **LIF** : Leukemia inhibiting factor
- **LTs** : Leukotrienes
- **MAP** : Mitogen-activated protein
- **MCP** : Membrane Co-factor protein
- **MMPs** : Matrix metalloproteinases
- **MUC** : Mucin
- **OC** : Oral contraceptives
- **OPN** : Osteopontin
- **PCOs** : Polycystic ovary syndrome

List of Abbreviations (Cont.)

- **PCT** : Post coital test
- **PGI₂** : Prostacyclin
- **PGS** : Prostaglandin Synthase
- **PGs** : Prostaglandins
- **PGT** : Prostaglandin transporter
- **PI** : Pulsatility Index
- **PID** : Pelvic Inflammatory Disease
- **PKC** : plausible substrates for cellular kinases C
- **PR** : Progesterone receptor
- **RGD** : Arginine- Glycine- Aspartic acid
- **RI** : Resistance Index
- **ROC** : Reciever Operating Characteristic curve
- **RPL** : Recurrent Pregnancy loss
- **SEM** : Scanning electron microscope
- **TGF** : Transforming growth factor
- **TNF- α** : Tumor Necrosis Factor α
- **TXa** : Thromboxanes
- **VEGF** : Vascular endothelial growth factor

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	World Health Organization Criteria for a Normal Semen Analysis (2010).....	15
Table (2):	Summary of events of the menstrual cycle.	23
Table (3):	Characteristics of patients in both study groups.....	141
Table (4):	Comparison of endometrial thickness, subendometrial Doppler indices, and $\alpha\beta 3$ -integrin score in both study groups.....	142
Table (5):	Receiver-operating characteristic (ROC) curve analysis for the discrimination between patients with unexplained infertility and normal controls using endometrial thickness, subendometrial Doppler indices, or $\alpha\beta 3$ -integrin score	145
Table (6):	Comparison of the receiver-operating characteristic (ROC) curves for the discrimination between patients with unexplained infertility and normal controls using endometrial thickness, subendometrial Doppler indices, or $\alpha\beta 3$ -integrin score.....	151

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	An example of a basal body temperature recording chart.	17
Figure (2):	Normal Hysterosalpingogram.....	19
Figure (3):	Illustrative diagram showing the days of fertile cycle	29
Figure (4):	Proposed model of integrin structure and activation.....	92
Figure (5):	Integrin conformation-function relationships	97
Figure (6):	Crystal Structure of the integrin $\alpha V\beta 3$ ectodomain.....	113
Figure (7):	Endometrial thickness of 3mm in case of the infertile group.	130
Figure (8):	Endometrial thickness of 10 mm in one of the fertile group.....	130
Figure (9):	Subendometrial blood flow Doppler showing decreased vascularity in a case of unexplained infertility group.	131
Figure (10):	Subendometrial blood flow Doppler showing good vascularity in one of control (fertile) group.....	131
Figure (11):	Endocell.	132
Figure (12):	Anti human $\alpha v\beta 3$ integrin Kit.	133
Figure (13):	H & E stained showing anovulatory endometrium in one of the unexplained infertility group, magnification x40.	134

List of Figures (Cont.)

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (14):	H & E stained showing early secretory endometrium in one of the unexplained infertility group, magnification x40.	135
Figure (15):	H & E stained showing secretory endometrium in one of the fertile group, magnification x200.	135
Figure (16):	Immunostained slide with anti- α v β 3 integrin, DAB chromogen, magnification x 200, score 0 in A case of unexplained infertility group.	136
Figure (17):	Immunostained slide with anti- α v β 3 integrin, DAB chromogen, magnification x 200, score 1 in A case of unexplained infertility group. Reactivity is mainly in the glandular epithelium.	136
Figure (18):	Immunostained slide with anti- α v β 3 integrin, DAB chromogen, magnification x 200, score 2 in A case of fertile group. Reactivity is mainly in the glandular epithelium + focally positive stromal cells + few blood vessels.	137
Figure (19):	Immunostained slide with anti- α v β 3 integrin, DAB chromogen, magnification x 40, score 3 in A case of fertility group. Reactivity is mainly in the glandular epithelium.	138
Figure (20):	Immunostained slide with anti- α v β 3 integrin,.....	138

List of Figures (Cont.)

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (21):	Mean endometrial thickness in both study groups.	143
Figure (22):	Mean subendometrial RI and PI in both study groups.	143
Figure (23):	Box plot showing the $\alpha\beta 3$ -integrin score in both study groups.....	144
Figure (24):	Receiver-operating characteristic (ROC) curve for the discrimination between patients with unexplained infertility and normal controls using endometrial thickness.....	147
Figure (25):	Receiver-operating characteristic (ROC) curve for the discrimination between patients with unexplained infertility and normal controls using subendometrial RI.	148
Figure (26):	Receiver-operating characteristic (ROC) curve for the discrimination between patients with unexplained infertility and normal controls using subendometrial PI.	149
Figure (27):	Receiver-operating characteristic curve for the discrimination between patients with unexplained infertility and normal controls using the $\alpha\beta 3$ -integrin score.	150
Figure (28):	Comparison of the receiver-operating characteristic (ROC) curves for the discrimination between patients with unexplained infertility and normal controls using endometrial thickness, subendometrial Doppler indices, or $\alpha\beta 3$ -integrin score.	152

Introduction

Unexplained infertility refers to the absence of a definable cause for a couple's failure to achieve pregnancy after 12 months of attempting conception despite a thorough evaluation (*Abusief et al., 2007*).

The Practice Committee of the American Society for Reproductive Medicine (ASRM) has published guidelines for a standard infertility evaluation (*The Practice Committee of the American Society for Reproductive Medicine, 2006*). It includes a semen analysis, assessment of ovulation, a hysterosalpingogram, and, if indicated, tests for ovarian reserve and laparoscopy. When the results of a standard infertility evaluation are normal, practitioners assign a diagnosis of unexplained infertility. Although estimates vary, the likelihood that all such test results for an infertile couple are normal (ie, that the couple has unexplained infertility) is approximately 15% to 30% (*The Practice Committee of the American Society for Reproductive Medicine, 2006*).

The average incidence of unexplained infertility has been reported to approximately 15%. The incidence varies from 0% to 37%. This variation may be attributed to selection bias in referral-based infertility practice (*Balasch, 2000*).

In the absence of a correctable abnormality, the therapy for unexplained infertility is, by default, empiric. Proposed treatment regimens include intrauterine insemination (IUI), ovulation induction with oral or injectable medications, combination of IUI with ovulation induction, and assisted reproductive technologies (ART) (*ASRM, 2006*).

Embryo implantation represents the most critical step of the reproductive process in many species. It consists of a unique biological phenomenon, by which the blastocyst becomes intimately connected to the maternal endometrial surface to form the placenta that will provide an interface between the growing fetus and the maternal circulation (*Denker, 1993; Aplin, 2000*).

Successful implantation requires a receptive endometrium, a normal and functional embryo at the blastocyst developmental stage and a synchronized dialogue between maternal and embryonic tissues (*Simonet et al., 2000*).

The process of implantation may be classified into three stages: apposition, adhesion and invasion (*Enders, 1967*).

The endometrium is receptive to blastocyst implantation during a spatially and temporally restricted window, called the implantation window. In humans, this period begins 6-10 days after the LH surge and lasts for 48 hours (*Simon et al., 2000*).

Endometrial receptivity consists in the acquisition of adhesion ligands together with the loss of inhibitory components that may act as a barrier to an attaching embryo (*Aplin, 2000*).

The relative inefficiency of the implantation process is paradoxical in view of the fact that reproduction is critical to species survival. Implantation failure remains an unsolved problem in reproductive medicine and is considered as a major cause of infertility in otherwise healthy women. Indeed, the average implantation rate in IVF is around 25% (*de los Santos et al., 2003*).

Inadequate uterine receptivity is responsible for approximately two-thirds of implantation failures, whereas the embryo itself is responsible for only one-third of these failures (*Simon et al., 1998; Ledee-Bataille et al., 2002*).

The recent discovery of molecules crucial for successful embryo implantation has offered researchers precious insight into this field. Primary adhesion molecules that are implicated in implantation include selectins, galectins, heparan sulfate proteoglycans, MUC1, integrins, cadherins, and the trophinin-tastin-bystin complex (*Dey et al., 2004*).

Integrins are a family of transmembrane glycoproteins, formed by the association of two different, non-covalently

linked, α and β subunits. To date, 18 α and eight β chains have been identified in mammals. When paired, they form 24 distinct integrin heterodimers that differ in their function (*Hynes, 2002*).

Integrins whose expression is increased in the mid-luteal phase were proposed as markers for the frame of the window of implantation (*Lessey et al., 2000*).

Three cycle-specific integrins are co-expressed by the human endometrium defined histologically on days 20–24 of the human menstrual cycle: $\alpha 1\beta 1$, $\alpha 4\beta 1$ and $\alpha v\beta 3$, but only the $\beta 3$ mRNA subunit expression was shown to increase after day 19 and is not detected beforehand. Moreover, $\alpha v\beta 3$ integrin as well as its ligand osteopontin was positively detected by Immunohistochemistry on the endometrial luminal epithelial surface, which first interacts with the trophoblast (*Apparao et al., 2001*).

In regard to its expression pattern along with its epithelial localization, $\alpha v\beta 3$ has been proposed as a potential receptor for embryonic attachment (*Lessey, 2003*).

Integrins are also expressed by the human trophoblast at the time of implantation (*Wang and Armant, 2002*).

During the proliferative phase, high estrogen levels act via the estrogen receptor- α (ER α) to inhibit integrin